The state of Washington currently has 23 active clinical trials seeking participants for Parkinson's Disease research studies. These trials are conducted in various cities, including Seattle, Spokane, Tacoma and Vancouver.
Use of CereGate Therapy for Freezing of Gait in PD
Recruiting
A Multi-Center, Controlled Study to Evaluate Use of CereGate Therapy to Reduce Freezing of Gait in Participants Diagnosed with Parkinson's Disease.
Gender:
All
Ages:
Between 21 years and 75 years
Trial Updated:
06/14/2024
Locations: University of Washington, Seattle, Washington
Conditions: Parkinson Disease, Freezing of Gait, Deep Brain Stimulation
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
Recruiting
The primary purpose of this study is to demonstrate the superiority of UCB0022 as an adjunctive treatment to stable dose of standard-of-care (SoC) (including at least levodopa therapy) over placebo with regard to motor fluctuations time spent in the OFF state (OFF time) in study participants with advanced Parkinson's Disease (PD).
Gender:
All
Ages:
Between 35 years and 80 years
Trial Updated:
06/13/2024
Locations: Pd0060 50292, Kirkland, Washington +1 locations
Conditions: Parkinson Disease
Registry of Deep Brain Stimulation With the VERCISEā„¢ System: Vercise DBS Registry
Recruiting
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated. Additionally, the utilization of the DBS Illumina 3D feature that may be... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Evergreen Health, Kirkland, Washington +2 locations
Conditions: Parkinson's Disease
Deep Brain Stimulation (DBS) Retrospective Outcomes Study
Recruiting
The primary objective of this study is to characterize real-world clinical outcomes of Deep Brain Stimulation (DBS) using retrospective review of de-identified patient records.
Gender:
All
Ages:
All
Trial Updated:
06/11/2024
Locations: Swedish Neuroscience Institute, Seattle, Washington
Conditions: Parkinson Disease, Essential Tremor, Dystonia
Early Parkinson's Disease Monotherapy With CVN424
Recruiting
This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on motor features with CVN424 tablets compared to placebo in early, untreated PD and to evaluate the potential of CVN424 to improve motor and non-motor functions in participants with early PD who are not t... Read More
Gender:
All
Ages:
30 years and above
Trial Updated:
06/04/2024
Locations: EvergreenHealth Neuroscience Institute, Kirkland, Washington +1 locations
Conditions: Parkinson's Disease
STEM-Parkinson's Disease
Recruiting
This is a double-blinded, controlled, randomized clinical trial (RCT) to establish the safety and efficacy of a non-invasive neuromodulation device for treating symptoms associated with Parkinson's disease.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
06/04/2024
Locations: Inland Northwest Research, Spokane, Washington
Conditions: Parkinson Disease, Parkinson's Disease and Parkinsonism
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
Recruiting
The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).
Gender:
All
Ages:
Between 35 years and 80 years
Trial Updated:
05/29/2024
Locations: Evergreen Neuroscience Institute, Kirkland, Washington +2 locations
Conditions: Parkinson's Disease
Parkinson's Foundation PD GENEration Genetic Registry
Recruiting
Development of a central repository for PD-related genomic data for future research.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/28/2024
Locations: Inland Northwest Research, Spokane, Washington
Conditions: Parkinson's Disease
The Parkinson's Genetic Research Study
Recruiting
The Parkinson's Genetic Research Study (PaGeR), headed by Dr. Cyrus Zabetian, is searching for genes that increase the risk of developing Parkinson's disease (PD) and related disorders. The study is a joint effort by neurologists and researchers across the United States and is sponsored by the National Institutes of Health. The coordinating center for PaGeR is located at the University of Washington and the VA Puget Sound Health Care System in Seattle.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/11/2024
Locations: VA Puget Sound Health Care System, Seattle, Washington +1 locations
Conditions: Parkinson's Disease
Pacific Northwest Udall Center (PANUC) Clinical Core
Recruiting
This study evaluates cognitive impairment in subjects with Parkinson disease (PD) and similar neurological disorder through obtaining longitudinal clinical and neuropsychological data. The long term goal is to have a well-characterized subject population to contribute to our understanding of the natural history, diagnosis and ultimate treatment of cognitive impairment in patients with PD and similar disorders.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/11/2024
Locations: VA Puget Sound Health Care System, Seattle, Washington
Conditions: Parkinson Disease, Cognitive Impairment
A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease
Recruiting
This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy and safety of suvecaltamide for the treatment of moderate to severe residual tremor in adult participants with Parkinson's disease (PD). The target population represents participants who have tremor that is not adequately controlled by PD medications and that interferes with their activities of daily living (ADL) and/or with their performance of tas... Read More
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
04/29/2024
Locations: EverGreenHealth Neuroscience Institute, Kirkland, Washington
Conditions: Parkinson Disease, Tremor
A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80
Recruiting
In this study, researchers will learn more about a study drug called BIIB122 in participants with early-stage Parkinson's disease (PD). In this study: Participants will take 225 milligrams (mg) of BIIB122 or a placebo as tablets by mouth. A placebo looks like the study drug but has no real medicine in it. Participants will take BIIB122 or placebo 1 time a day for up to a minimum of 48 weeks and a maximum of 144 weeks. Certain medications for PD will be allowed at enrollment for a subset of part... Read More
Gender:
All
Ages:
Between 30 years and 80 years
Trial Updated:
04/17/2024
Locations: Evergreen Hospital Medical Center, Kirkland, Washington +1 locations
Conditions: Parkinson Disease